From Dr Reddy\'s to Cipla\, pharma companies aren\'t out of the woods: Experts

From Dr Reddy's to Cipla, pharma companies aren't out of the woods: Experts

The Street is cautious given multiple challenges in core markets of US and India

Ujjval Jauhari  |  New Delhi 

The BSE Healthcare Index hit an all-time low last week and continues to trade weak due to multiple headwinds. Despite easing competitive intensity in the US and lower price erosion, the sector does not seem to be out of the woods. There are multiple pain points for the sector in the core markets of the US and India which are pegging back the growth prospects.

First, the US market. Near-term growth in this lucrative geography hinges on timely approval for large products, regulatory clearances and success of speciality products. Even though Indian companies are on a strong footing and ...

Note: Subscription will be auto renewed, you may cancel any time in the future without any questions asked.

Total Amount
Rs. 149.00
Requires personal information

What you get?

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all the content on any device through browser or app.
  • Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.
  • 18 years of archival data.
  • Requires you to share personal information like date of birth, income, location amongst other fields. This information alongwith your contact information will be shared with the partners associated with this program, who contribute towards subsidizing the offer. By subscribing to this product you acknowledge and accept that our Partners may choose to contact you with offers of their products and services.
  • This is an optional offer - Not comfortable with sharing personal data - please opt for the full price offer which requires you to share minimal information
Read our full coverage on pharma firms
First Published: Sun, August 18 2019. 20:11 IST